Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRaG 5.0: Thymalfasin-regulated therapy for advanced refractory solid tumors
NCT05790447Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Apr 2023
- Primary completion
- May 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of thymosin alpha 1 in solid tumor (advanced stage), sponsored by The Second Affiliated Hospital of Soochow University. Started Apr 2023; status: recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05790447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05790447.